Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place

Journal of Urology

Volumn 162, Issue 1, 1999, Pages 43-45

  Wagner, Joseph R ^a   Walther, McClellan M ^a   Linehan, W Marston ^a   White, Donald E ^a   Rosenberg, Steven A ^a   Yang, James C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinoma, renal cell; Interleukin 2; Kidney; Kidney neoplasms; Neoplasm metastasis

Indexed keywords

INTERLEUKIN 2;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DIARRHEA; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0032883614     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199907000-00011     Document Type: Article

References (24)

1. Savage, P. D, and Muss, H. B.: Biologic therapy with interferon-alpha and beta: applications/renal cancer. In: Biologic Therapy of Cancer. Edited by V. T. DeVita, S. Hellman and S. Rosenberg. Philadelphia: Lippincott, p. 373, 1995.
2. Yang, J. C.: Biologic therapy with interleukin-2: clinical applications/renal cancer. In: Biologic Therapy of Cancer. Edited by V. T. DeVita, S. Hellman and S. Rosenberg. Philadelphia: Lippincott, p. 262, 1995.
3. Walther, M. M., Yang, J. C., Pass, H. I., Linehan, W. M. and Rosenberg, S. A.: Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J. Urol., 158: 1675, 1997.
4. Franklin, J. R., Figlin, R., Rauch, J., Gitlitz, B. and Belldegrun, A.: Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Sem. Urol Oncol., 14: 230, 1996.
5. Walther, M. M., Alexander, R. B. and Weiss, G. H.: Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology, 42: 250, 1993.
6. Bennett, R. T., Lerner, S. E., Taub, H. C., Dutcher, J. P. and Fleischmann, J.: Cytoreductive surgery for stage IV renal cell carcinoma. J. Urol., 154: 32, 1995.
7. Spencer, W. F., Linehan, W. M., Walther, M. M., Haas, G. P., Lotze, M. T., Topalian, S. L., Yang, J. C., Merino, M. J., Lange, J. R., Pockaj, B. A. and Rosenberg, S. A.: Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J. Urol., 147: 24, 1992.
8. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S. and White, D. E.: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol., 7: 1863, 1989.
9. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Aebersold, P. M., Linehan, W. M., White, D. E. and Seipp, C. A.: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg., 210: 474, 1989.
10. Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P. M., Leitman, S., Linehan, W. M. and Seipp, C. A.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst., 85: 622, 1993.
11. Yang, J. C., Topalian, S. L., Parkinson, D., Schwartzentruber, D. S., Weber, J. S., Ettinghausen, S. E., White, D. E., Steinberg, S. M., Cole, D. J. and Kim, H. I.: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol., 12: 1572, 1994.
12. Lange, J. R., Raubitschek, A. A., Pockaj, B. A., Spencer, W. F., Lotze, M. T., Topalian, S. L., Yang, J. C. and Rosenberg, S. A.: A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J. Immunother., 12: 265, 1992.
13. Yang, J. C. and Rosenberg, S. A.: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J. Sci. Amer., suppl., 3: S79, 1997.
14. Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Parkinson, D. R., Marincola, F. M., Weber, J. S., Seipp, C. A., White, D. E. and Rosenberg, S. A.: The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2. Cancer, 76: 687, 1995.
15. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics. CA, 46: 5, 1996.
16. Johnson, D. E., Kaesler, K. E. and Samuels, M. L.: Is nephrectomy justified in patients with metastatic renal carcinoma. J. Urol., 114: 27, 1975.
17. Montie, J. E., Stewart, B. H., Straffon, R. A., Banowsky, L. H., Hewitt, C. B. and Montague, D. K.: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol., 117: 272, 1977.
18. Freed, S. Z,: Nephrectomy for renal cell carcinoma with metastases. Urology, 9: 613, 1977.
19. Rackley, R., Novick, A., Klein, E., Bukowski, R., McLain, D. and Goldfarb, D.: The impact of adjuvant nephrectomy on multi-modality treatment of metastatic renal cell carcinoma. J. Urol., 152: 1399, 1994.
20. Wolf, J. S., Aronson, F. R., Small, E. J. and Carroll, P. R.: Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J. Surg. Oncol., 55: 7, 1994.
21. Walther, M. M., Lyne, J. C., Libutti, S. K. and Linehan, W. M.: Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology, 53: 496, 1999.
22. Fleischmann, J.D. and Kim, B.: Interleukin-2 immunotherapy followed by resection of residual renal cell carcinoma. J. Urol., 145: 938, 1991.
23. Haas, G. P., Redman, B. G., Rao, V. K., Dybal, E., Pontes, J. E. and Hillman, G. G.: Immunotherapy for metastatic renal cell cancer: effect on the primary tumor. J. Immunother., 13: 130, 1993.
24. Rosenberg, S. A., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H. and White, D. E.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin 2. J.A.M.A., 271: 907, 1994.